‘Greed-Driven Scheme’: Molekule Hit with Another Class Action Over Air Purifier Efficacy Claims [UPDATE]
Last Updated on November 16, 2021
Apaliski et al. v. Molekule, Inc.
Filed: November 17, 2020 ◆§ 1:20-cv-01548
A class action alleges Molekule's air purification devices fall well short of the company's performance claims.
Case Updates
November 16, 2021 – File a Claim: Molekule Air Purifier Settlement Website Is Live
The official settlement website for the Molekule air purifier class action is live and can be found here:
https://airpurifiersettlement.com/index.html
To file a claim online, head to this page and input your information, including the class member ID included with your settlement notice. Consumers who file a claim under “Group A” are required to attach an image of their proof of purchase for each Molekule air purifier they bought. Those who file under “Group B” do not have to submit proof of purchase but will be entitled to less in settlement benefits.
The website states that the average payout a class member can expect to receive from the settlement, if they purchased one air purifier, is $43.80. This amount may vary for each consumer based on the total number of claims filed, the specific model purchased and whether proof of purchase is submitted with a claim.
Eligible claims must be submitted online or postmarked by May 31, 2022. In most circumstances, consumers will have to submit a claim form in order to receive benefits from the settlement.
November 16, 2021 – File a Claim: Molekule Air Purifier Settlement Website Is Live
The official settlement website for the Molekule air purifier class action is live and can be found here:
https://airpurifiersettlement.com/index.html
To file a claim online, head to this page and input your information, including the class member ID included with your settlement notice. Consumers who file a claim under “Group A” are required to attach an image of their proof of purchase for each Molekule air purifier they bought. Those who file under “Group B” do not have to submit proof of purchase but will be entitled to less in settlement benefits.
The website states that the average payout a class member can expect to receive from the settlement, if they purchased one air purifier, is $43.80. This amount may vary for each consumer based on the total number of claims filed, the specific model purchased and whether proof of purchase is submitted with a claim.
Eligible claims must be submitted online or postmarked by May 31, 2022. In most circumstances, consumers will have to submit a claim form in order to receive benefits from the settlement.
The 87-page lawsuit alleges Molekule’s Air, Air Mini and Air Mini+ air purification devices are defective in that the proprietary Photo Electrochemical Oxidation (PECO) filter used by the products, touted by the defendant as “the world’s first molecular air purifier,” not only perform worse than traditional HEPA air filters but also do not remove any pollutants from the air.
Filed November 17 by four plaintiffs in Delaware federal court, the complaint alleges Molekule, in marketing the products, has issued a number of misrepresentations concerning the air purifiers’ performance, abilities and benefits. The suit claims Molekule has misrepresented that the air purifiers:
- Use PECO filter technology that “outperforms HEPA filters in every category of pollutant”;
- Are able to “eradicate[] the full spectrum of indoor air pollutants”;
- Are capable of achieving quantified pollution-removal benchmarks, i.e. “destroy[ing] 1 million allergens in 4 minutes”;
- Were subject to “independent testing” that served as the basis for Molekule’s marketing claims;
- Are rated to function in rooms of certain sizes;
- Provide allergy and asthma symptom relief; and
- Fight “unhealthy levels” of wildfire smoke considering the products are marketed as able to not only filter out ash and debris but destroy airborne pollutants.
Moreover, Molekule has “tailored its advertising to capitalize on current events” by claiming its Air Purifiers “destroy” coronavirus, the lawsuit says.
“Defendant engaged in a deceptive and misleading marketing campaign to sell Air Purifiers based on misrepresentations and omissions that it spread through its own website, social media, interviews with third-party publications, YouTube, and other fora,” the complaint alleges. “Defendant’s green-driven scheme is at the expense of consumers across the country and in violation of applicable law.”
According to the suit, Molekule’s representations do not hold up under scrutiny. Consumer Reports, for instance, stated the Molekule Air “almost flunked” the standard battery of tests through which the publication puts air purifiers, the case says. Per the suit, the products fared no better in a review conducted by New York Times tech review affiliate site Wirecutter, who described the air purifiers in October 2019 as “[t]he worst air purifier we’ve ever tested.”
Wirecutter focused in particular on Molekule’s claim that its PECO filters outperformed HEPA filters, the case says. The lawsuit states that Wirecutter’s tests, in which the Molekule Air went head to head against HEPA filter devices, revealed that “on every single setting the Molekule Air produced results that were substantially worse than its competition.”
“Indeed, on the lowest setting, the Molekule Air ‘results look worse than what you see with no purifier running at all,’” the complaint reads, claiming the defendant scrubbed the contested claim from its website following the publication of this review.
Consumers such as the plaintiffs bought Molekule’s air purifiers based on the company’s false and misleading representations, the lawsuit says. The case scathes that the defendant’s ads are “replete with misrepresentations” that motivate consumers to buy products, which are reportedly “among the most expensive available” yet fail on every advertised metric and “offer[] no therapeutic benefit whatsoever.”
Get class action lawsuit news sent to your inbox – sign up for ClassAction.org’s newsletter here.
Before commenting, please review our comment policy.